Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABNGM:PRLD -5.24%30 Cash-to-Debt is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates NGM:PRLD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks better than 99.52% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prolight Diagnostics AB's cash to debt ratio for the quarter that ended in Jun. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prolight Diagnostics ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Prolight Diagnostics AB's Cash-to-Debt or its related term are showing as below:
NGM:PRLD'
s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
During the past 10 years, Prolight Diagnostics AB's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.
NGM:PRLD's Cash-to-Debt is ranked better than 99.52% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs NGM:PRLD: No Debt
Prolight Diagnostics AB (NGM:PRLD) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Prolight Diagnostics AB Cash-to-Debt Related Terms
Prolight Diagnostics AB Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NGM:PRLD vs ISRG, BDX, RMD: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's Cash-to-Debt falls into.
Prolight Diagnostics AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
Prolight Diagnostics AB had no debt (1).
Prolight Diagnostics AB's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:
Prolight Diagnostics AB had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Prolight Diagnostics AB (NGM:PRLD) has a Cash-to-Debt of No Debt (1) as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Prolight Diagnostics AB's Cash-to-Debt has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Prolight Diagnostics AB ranks #4 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 0.5%.
Is Prolight Diagnostics AB's Cash-to-Debt too high?
Prolight Diagnostics AB's current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Prolight Diagnostics AB ranks #4 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prolight Diagnostics AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #4 out of 842 companies for Cash-to-Debt. This places Prolight Diagnostics AB in the top 1% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.64. Historically, Prolight Diagnostics AB's own Cash-to-Debt has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (NGM:PRLD) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Prolight Diagnostics AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Prolight Diagnostics AB (NGM:PRLD), the current Cash-to-Debt is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
30GF Score
Get the complete analysis for NGM:PRLD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:PRLD has been successfully added to your 
